Results 191 to 200 of about 288,435 (354)

Metabolic Parameters on Baseline and Early [18F]FDG PET/CT as a Predictive Biomarker for Resistance to BRAF/MEK Inhibition in Advanced Cutaneous BRAFV600-mutated Melanoma [PDF]

Bernies van der Hiel, Berlinda J. de Wit–van der Veen, Alfons J.M. van den Eertwegh, Wouter V. Vogel, Marcel P. M. Stokkel, Marta López‐Yurda, Ronald Boellaard, Ellen Kapiteijn, Geke A.P. Hospers, Maureen J.B. Aarts, Filip De Vos, Marye J. Boers‐Sonderen, Astrid A.M. van der Veldt, Jan Willem B. de Groot, John B.A.G. Haanen   +14 more
openalex   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

Advanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu   +4 more
wiley   +1 more source

Population Mortality in Advanced Melanoma Patients with and Without Response and Progression; Data from the Dutch Melanoma Treatment Registry

, 2022
Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense, Gerard Vreugdenhil, Marye J. Boers‐Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede   +18 more
openalex   +1 more source

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma [PDF]

, 2023
Rachel Goodman, Lorenza Di Guardo, Andrea Maurichi, Brendan Kirwin, Adnan Khattak, Vito Vanella, Joanna Lee, Aleigha Lawless, Juliane Czapla, A. Spagnoletti, Margherita Ambrosini, Elisabeth Livingstone, Georgina V. Long, Ryan J. Sullivan, Matteo S. Carlino, Victoria Atkinson, Claudia Trojanello, Paolo A. Ascierto, Dirk Schadendorf, Lydia Warburton, Alexander M. Menzies, Mario Santinami, Douglas B. Johnson   +22 more
openalex   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data. [PDF]

Cancers (Basel)
Blumenröther AK, Fang Y, El Saadany T, Ramelyte E, Hasan Ali O, Kündig T, Mihic-Probst D, Steiner S, Maurer A, Dummer R, Mangana J, Maul LV.   +11 more
europepmc   +1 more source

A Study of the Clinical Characteristics and Prognosis Of Advanced Mucosal and Cutaneous Melanoma in a Chinese Population [PDF]

, 2018
Yong Zhang, Xiaomin Fu, Yalong Qi, Quanli Gao   +3 more
openalex   +1 more source

Advanced Uveal Melanoma [PDF]

, 2020
openaire   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma. [PDF]

J Immunother Cancer
Yamada MM, Chandrasekhar S, Gooley TA, Chen RE, Doolittle-Amieva C, Ansstas G, Bhatia S, Hall ET, Nghiem PT, Park SY, Chen DY.   +10 more
europepmc   +1 more source